Neophore was launched by University of Cambridge biopharmaceutical developer PhoreMost in May 2017 to home in on potential immunotherapies for cancer.

Neophore, a UK-based oncological offshoot of biopharmaceutical developer and University of Cambridge spinout PhoreMost, has raised £3m ($3.9m) in capital from CRT Pioneer Fund, an oncology-focused investment fund managed by Sixth Element Capital.
CRT Pioneer Fund is a partnership between the EU-owned European Investment Fund and Cancer Research Technology, the commercialisation arm of charity Cancer Research UK.
Founded in May 2017, Neophore is developing small molecule-based cancer treatments that aim to stimulate the production of neoantigens created as…